Perturbed Mitochondrial Dynamics Is a Novel Feature of Colitis That Can Be Targeted to Lessen Disease

Cell Mol Gastroenterol Hepatol. 2020;10(2):287-307. doi: 10.1016/j.jcmgh.2020.04.004. Epub 2020 Apr 13.

Abstract

Background & aims: Mitochondria exist in a constantly remodelling network, and excessive fragmentation can be pathophysiological. Mitochondrial dysfunction can accompany enteric inflammation, but any contribution of altered mitochondrial dynamics (ie, fission/fusion) to gut inflammation is unknown. We hypothesized that perturbed mitochondrial dynamics would contribute to colitis.

Methods: Quantitative polymerase chain reaction for markers of mitochondrial fission and fusion was applied to tissue from dextran sodium sulfate (DSS)-treated mice. An inhibitor of mitochondrial fission, P110 (prevents dynamin related protein [Drp]-1 binding to mitochondrial fission 1 protein [Fis1]) was tested in the DSS and di-nitrobenzene sulfonic acid (DNBS) models of murine colitis, and the impact of DSS ± P110 on intestinal epithelial and macrophage mitochondria was assessed in vitro.

Results: Analysis of colonic tissue from mice with DSS-colitis revealed increased mRNA for molecules associated with mitochondrial fission (ie, Drp1, Fis1) and fusion (optic atrophy factor 1) and increased phospho-Drp1 compared with control. Systemic delivery of P110 in prophylactic or treatment regimens reduced the severity of DSS- or DNBS-colitis and the subsequent hyperalgesia in DNBS-mice. Application of DSS to epithelial cells or macrophages caused mitochondrial fragmentation. DSS-evoked perturbation of epithelial cell energetics and mitochondrial fragmentation, but not cell death, were ameliorated by in vitro co-treatment with P110.

Conclusions: We speculate that the anti-colitic effect of systemic delivery of the anti-fission drug, P110, works at least partially by maintaining enterocyte and macrophage mitochondrial networks. Perturbed mitochondrial dynamics can be a feature of intestinal inflammation, the suppression of which is a potential novel therapeutic direction in inflammatory bowel disease.

Keywords: DNBS; DSS; epithelium; inflammation; macrophage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Colitis, Ulcerative / chemically induced
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / immunology*
  • Colitis, Ulcerative / pathology
  • Colon / cytology
  • Colon / drug effects
  • Colon / immunology
  • Colon / pathology*
  • Dextran Sulfate / administration & dosage
  • Dextran Sulfate / toxicity
  • Disease Models, Animal
  • GTP Phosphohydrolases / pharmacology*
  • GTP Phosphohydrolases / therapeutic use
  • Humans
  • Intestinal Mucosa / cytology
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / immunology
  • Intestinal Mucosa / pathology*
  • Male
  • Mice
  • Mitochondria / drug effects
  • Mitochondria / immunology
  • Mitochondria / metabolism
  • Mitochondrial Dynamics / drug effects
  • Mitochondrial Dynamics / immunology*
  • Oxidative Stress / drug effects
  • Oxidative Stress / immunology
  • Peptide Fragments / pharmacology*
  • Peptide Fragments / therapeutic use

Substances

  • P110 peptide
  • Peptide Fragments
  • Dextran Sulfate
  • GTP Phosphohydrolases

Grants and funding